NF1 deletion
|
GBM
|
NF1 deletion
|
GBM
|
PD-0325901 Sensitive: C4 – Case Studies
|
PD-0325901 Sensitive: C4 – Case Studies
|
NF1 deletion
|
Breast Cancer
|
NF1 deletion
|
Breast Cancer
|
zoledronic acid Sensitive: D – Preclinical
|
zoledronic acid Sensitive: D – Preclinical
|
NF1 deletion
|
Breast Cancer
|
NF1 deletion
|
Breast Cancer
|
vincristine Sensitive: D – Preclinical
|
vincristine Sensitive: D – Preclinical
|
NF1 deletion
|
AML
|
NF1 deletion
|
AML
|
CI-1040 Resistant: D – Preclinical
|
CI-1040 Resistant: D – Preclinical
|
NF1 deletion
|
AML
|
NF1 deletion
|
AML
|
PD-0325901 Resistant: D – Preclinical
|
PD-0325901 Resistant: D – Preclinical
|
NF1 deletion
|
Melanoma
|
NF1 deletion
|
Melanoma
|
trametinib + AZ 628 Sensitive: D – Preclinical
|
trametinib + AZ 628 Sensitive: D – Preclinical
|